BIONEWS
Cologne researchers trace that risk to EPS8, a scaffolding protein that drives toxic aggregates in worm and human cell models as it piles up with age.
Aging is the single largest risk factor for neurodegenerative disease, and scientists have never had a clean molecular explanation for why. A new paper in Nature Aging from the CECAD Cluster of Excellence at the University of Cologne names a candidate: a scaffolding protein called EPS8 that piles up with age and, in worm and human cell models of amyotrophic lateral sclerosis (ALS) and Huntington's, an inherited neurodegenerative disease, drives the toxic protein clumps that kill neurons (ScienceDaily summary of the University of Cologne release; Nature Aging paper, "The aging factor EPS8 induces disease-related protein aggregation through RAC signaling hyperactivation").
Dr. Seda Koyuncu and Prof. David Vilchez at CECAD report the most specific mechanistic candidate to date for the aging and neurodegeneration link. In C. elegans, a one-millimeter nematode worm used as a model because its cellular machinery is highly conserved with humans, reducing EPS8 prevented the formation of toxic huntingtin and ALS-associated protein aggregates and preserved neuronal function. The same knockdown blocked aggregate formation in human cell models of both diseases, suggesting the pathway travels across species.
RAC, a cellular signaling cascade, sits at the center of the proposed mechanism. EPS8 appears to switch it on past its normal range as the protein accumulates, and the Vilchez group shows that dialing EPS8 back normalizes RAC activity and prevents the clumping. The piece the source itself flags as unresolved is the precise molecular step between runaway RAC signaling and the formation of toxic aggregates (PubMed record 40903652).
The work is in worms and human cell lines. It is not a treatment and it has not been tested in mice or people. Any therapeutic claim built on it now would be premature, and the field's history of worm-to-human translation is mixed. The first wave of anti-aggregation drug candidates in the 2000s looked clean in cell and worm models and failed in clinical trials, a record that has made geroscience more careful about how it stages its claims.
EPS8 sits outside the usual target list because it is defined by aging rather than by a specific disease. The dominant drug targets in neurodegeneration, amyloid in Alzheimer's, huntingtin in Huntington's, SOD1 and TDP-43 in ALS, are all tied to a particular condition. Geroscience has argued for two decades that targeting the aging side of the equation is the more tractable move, and that approach has been drawing serious pharma funding in recent years.
The drugs that have come closest to that approach so far are familiar names: rapamycin, an immunosuppressant whose mTOR-inhibiting properties extend healthy lifespan in animal studies; metformin, a cheap diabetes drug whose users show lower rates of age-related disease in observational data; and a newer class of senolytics that clear senescent cells. A small molecule against EPS8, or against one of its RAC-signaling partners, would slot into a pipeline that already exists rather than requiring a new one.
The next concrete step is a mammalian test. The Vilchez lab has the worm and cell data. The field now needs mouse models of age-related EPS8 accumulation, a clearer map of the EPS8-to-aggregation step the paper leaves open, and a small-molecule screen against EPS8 or its RAC partners. All three are standard moves in the geroscience drug-development pipeline. Until those land, EPS8 is a named suspect, not a cure.